Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus sorafenib versus gemcitabine plus placebo in advanced biliary tract cancer
2007-005796-34Phase 2Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in biliary adenocarcinoma, cholangiocarcinoma (CCA) and gallbladder adenocarcinoma comparing Gemcitabine plus sorafenib with Gemcitabine plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Jan 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
biliary adenocarcinomacholangiocarcinoma (CCA)gallbladder adenocarcinoma
Beyond the preview
Go deeper on 2007-005796-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005796-34.